Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857827 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
A Phase 2 study, sponsored by Qlaris Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04857827 is a Phase 2 study that has completed, run by Qlaris Bio. The registered enrollment target is 30 participants.
The verdict
NCT04857827, a Phase 2 study, has completed, sponsored by Qlaris Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension glaucoma
Interventions
- DRUG QLS-101
- DRUG Timolol maleate PF 0.5% ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2022-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857827
The ClinicalTrials.gov registry entry for NCT04857827 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qlaris Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QLS-101 is the first listed.
NCT04857827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04857827 about?
NCT04857827 is a clinical study titled "A Study to Evaluate Safety and Tolerability of QLS-101 in NTG". A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension glaucoma
What is the current status of trial NCT04857827?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-09-15. Estimated completion is 2022-08-26.
What interventions are being tested in trial NCT04857827?
The interventions under investigation include: QLS-101 (DRUG), Timolol maleate PF 0.5% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT04857827?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.